Creating needs? A review of survey data and concerns relevant to the commercialization of genetic testing

Community Genetics

Volumn 4, Issue 2, 2001, Pages 68-76

  Caulfield, Timothy ^a   Wertz, Dorothy ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Commercialization; Genetic testing; Marketing of genetic tests; Public perceptions of genetic testing; Regulatory policy

Indexed keywords

ATTITUDE; COMMERCIAL PHENOMENA; GENE TECHNOLOGY; GENETIC ANALYSIS; HUMAN; INFORMATION; LABORATORY; MARKET; PERCEPTION; PRIORITY JOURNAL; PUBLIC OPINION; REVIEW; ADVERTIZING; ECONOMICS; ETHICS; GENETIC SCREENING; GENETIC SERVICE; GENETICS AND REPRODUCTION; HEALTH CARE DELIVERY; HUMAN RIGHTS; INFORMATION PROCESSING; NORTH AMERICA; RISK ASSESSMENT; SOCIAL CONTROL; UTILIZATION REVIEW;

GENETICS AND REPRODUCTION;

ADVERTISING; ATTITUDE; ATTITUDE OF HEALTH PERSONNEL; COMMERCE; CONFLICT OF INTEREST; DATA COLLECTION; GENETIC SCREENING; GENETIC SERVICES; HEALTH SERVICES ACCESSIBILITY; KNOWLEDGE, ATTITUDES, PRACTICE; NORTH AMERICA; PERSONAL AUTONOMY; PUBLIC OPINION; RISK ASSESSMENT; SOCIAL CONTROL, FORMAL;

EID: 0034768775     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051160     Document Type: Review

References (86)

1. State of the Art of Genetic Testing in the United States: Survey of biotechnology companies and nonprofit clinical laboratories and interviews of selected organizations. Appendix 3
2. Commentary: Risks and benifits, testing and screening, cancer, genes and dollars
3. Implications of the Human Genome Project for medical science
4. The commercialization of human genetics: A discussion of issues relevant to Canadian consumers
5. A false start? The impact of federal policy on the genotechnology industry
6. Predictive genetic diagnosis
7. Is genetic testing premature?
8. Genes, disease and medicine
9. Pitfalls of genetic testing
10. BRCA1 - Lots of mutations, lots of dilemmas
11. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women
12. BRCA Genes - Bookmaking, fortunetelling, and medical care
13. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
14. Breast Cancer Working Group of the Stanford Program in Genomics, Ethics and Society: Genetic testing for BRCA1 and BRCA2: Recommendations of the Stanford Program in Genomics, Ethics and Society
15. The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer disease
16. The future of genetic counselling: An international perspective
17. The Human Genome Project: Under an international ethical microscope
18. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis
19. Quality assurance in molecular genetic testing laboratories
20. Mixed messages: Presentation of information in cystic fibrosis-screening pamphlets
21. Informational materials about genetic tests. Appendix 4
22. The new eugenics and medicalized reproduction
23. The persistence of eugenics
24. The politics of health: Geneticization versus health promotion
25. Past as prologue: Sobering thoughts on genetic enthusiasm
26. Disease gene patents: Overcoming unethical constraints on clinical laboratory medicine
27. News: Myriad's rationale for wider testing
28. News: Testing, testing ... testing?
29. Professional autonomy vs. industrial control?
30. Regulating pharmaceutical advertising: What will work?
31. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians
32. News: Direct to consumer drug ads spark debate
33. Genetic testing for cancer risk: A population survey on attitudes and intention
34. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2
35. Men's attitudes regarding genetic testing for hereditary prostate cancer risk
36. Sons of men with prostate cancer: Their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing
37. Hereditary cancer risk notification and testing: How interested is the general population?
38. Genetic testing for breast cancer susceptibility: Awareness and interest among women in the general population
39. Interest in genetic testing among first-degree relatives of breast cancer patients
40. Most Canadians welcome genetic testing
41. Attitudes of 47 mothers of pediatric oncology patients toward genetic testing for cancer predisposition
42. Women's receptivity to testing for a genetic susceptibility to breast cancer
43. Allocating health resources ethically: New roles for administrators and clinicians
44. Rights, duties, and limits of autonomy
45. Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility
46. Patient and professional views on autonomy: A survey in the United States and Canada
47. Ethical issues in pediatric genetics: Views of geneticists, parents and primary care physicians
48. Attitudes towards genetic testing: Analysis of contradictions
49. Uptake and impact of carrier testing for cystic fibrosis
50. Reluctance to undergo predictive testing: The case of Huntington disease
51. Are genetic tests adequately regulated?
52. Genetic counselling and hereditary breast cancer
53. Genetic testing in families with hereditary nonpolyposis colon cancer
54. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing
55. Motivations, perceptions, and interpersonal differences associated with interest in genetic testing for breast cancer susceptibility among women at high and average risk
56. Commercialization of BRCA1/2 testing: Practitioner awareness and use of a new genetic test
57. A descriptive study of BRCA1 testing and reactions to disclosure of test results
58. Genetic discrimination: Perspectives of consumers
59. Uptake of cystic fibrosis testing in primary care: Supply push or demand pull
60. Attitudes of obstetrician-gynecologists toward DNA testing for a genetic susceptibility to breast cancer
61. Group drafts core curriculum for 'What docs need to know about genetics'
62. Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients
63. Are practicing and future physicians prepared to obtain informed consent? The case of genetic testing for susceptibility to breast cancer
64. Professional perspectives: A survey of Canadian providers
65. Biotechnology, genetic information and community?; From individual rights to social duties?
66. NRTs: Is criminalization the solution for Canada?
67. Genetic testing and screening: The developing European jurisprudence
68. The disability rights critique of prenatal genetic testing: Reflections and recommendations
69. Regulating the commercialization of human genetics: Can we address the big concerns?
70. Restricting reproductive freedom is the real indignity
71. Public participation in medical policy-making and the status of consumer autonomy: The example of newborn screening programs in the United States